ArticleJournal of arrhythmia2025
Updated Meta-Analysis of Catheter Ablation Versus Medical Therapy in Atrial Fibrillation With Heart Failure With Preserved Ejection Fraction.
Article in Journal of arrhythmia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The effect of beta-blockers in heart failure with preserved ejection fraction and atrial fibrillation: systematic review and meta-analysis.Irish journal of medical science · 2026Article
- Catheter Ablation Versus Medical Therapy in Atrial Fibrillation With Heart Failure With Reduced or Mildly Reduced Ejection Fraction: A GRADE-Assessed Systematic Review and Meta-Analysis.Journal of arrhythmia · 2026Article
- Management of recurrent atrial fibrillation after catheter ablation: 5-year outcomes of repeat catheter ablation vs. antiarrhythmic therapy.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- Catheter ablation of atrial fibrillation in patients with heart failure - preserved and reduced ejection fraction - real world evidence.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Article
- Atrial Fibrillation Ablation in Patients With Heart Failure and Preserved Ejection Fraction: Faux Pas, Great Absences, and New Hopes.Journal of arrhythmia · 2026Article
- Updated Meta-Analysis of Catheter Ablation Versus Medical Therapy in Atrial Fibrillation With Heart Failure With Preserved Ejection Fraction.Journal of arrhythmia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The advantage of catheter ablation compared to medical therapy for atrial fibrillation (AF) in patients diagnosed with heart failure with preserved ejection fraction (HFpEF) remains indeterminate. A meta-analysis was conducted to assess outcomes within this population. Methods: We searched MEDLINE, Embase, Cochrane CENTRAL, and ClinicalTrials.gov through May 2025. Twelve studies satisfied the inclusion criteria, encompassing a total sample size of 43 584 individuals. Outcomes included primary composite endpoints, HF hospitalizations, all-cause mortality, AF recurrence, cardiovascular (CV) mortality, all-cause hospitalization, and stroke. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using random-effects models; heterogeneity was assessed using Results: Catheter ablation notably reduced the primary composite endpoint (HR, 0.53; 95% CI, 0.41-0.68; Conclusion: In patients with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF), catheter ablation is correlated with substantially enhanced outcomes compared to medical therapy, particularly in decreasing composite events, mortality, and the incidence of stroke. Trial Registration: PROSPERO (CRD420251069889).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.